Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Sep;182(17):3990-3993.
doi: 10.1111/bph.70136. Epub 2025 Jul 11.

SGLT2 inhibitors and their influence on iron metabolism in the context of inflammation

Helene G Meyer  1 , Chiara Tinner  1 , Chloé Sieber  2   3 , Dirk Lehnick  2   3 , Balthasar Hug  1   4
Affiliations

SGLT2 inhibitors and their influence on iron metabolism in the context of inflammation

Helene G Meyer et al. Br J Pharmacol. 2025 Sep.

Abstract

Background and purpose: Sodium-glucose linked transporter 2 (SGLT2) inhibitors stimulate erythropoietin, resulting in increased iron utilization. Consequently, patients often have biomarkers indicating iron deficiency. Here we have assessed the relationship between SGLT2 inhibitors and iron biomarkers in anaemic patients with inflammation.

Experimental approach: This retrospective cross-sectional study included patients with anaemia (WHO definition) and inflammation. We performed bivariate analyses (one-way ANOVA) on log-transformed and original values of soluble transferrin-receptor and ferritin index, both markers of iron stores in the presence of inflammation. Three-way ANOVA models assessed the effect of SGLT2 inhibitors on these biomarkers, adjusting for congestive heart failure and diabetes mellitus.

Key results: Of the 439 participants, 55 were taking SGLT2 inhibitors. One-way ANOVA showed higher log-transformed soluble transferrin-receptor values in SGLT2 inhibitor users. However, when congestive heart failure and diabetes mellitus were controlled for in the three-way ANOVA, the association disappeared. Similar patterns were observed for soluble transferrin-receptor and ferritin index. All models explained only a small proportion of variance in iron biomarkers.

Conclusion and implications: Our bivariate analysis showed a clear association between SGLT2 inhibitors and iron biomarkers in the presence of inflammation. However, this association disappeared when the model was controlled for congestive heart failure and diabetes mellitus. The apparent association may be due to factors other than inhibition of SGLT2. Clinicians should prioritize diagnosing and managing iron metabolism disorders in high-risk populations, such as those with heart failure, regardless of SGLT2 inhibitor use.

Keywords: anaemia of inflammation; heart failure; iron biomarker; iron deficiency.

PubMed Disclaimer

References

REFERENCES

    1. Docherty, K. F., McMurray, J. J. V., Kalra, P. R., Cleland, J. G. F., Lang, N. N., Petrie, M. C., Robertson, M., & Ford, I. (2024). Intravenous iron and SGLT2 inhibitors in iron‐deficient patients with heart failure and reduced ejection fraction. ESC Heart Failure, 11, 1875–1879. https://doi.org/10.1002/EHF2.14742
    1. Ganz, T. (2019). Anemia of inflammation. New England Journal of Medicine, 381, 1148–1157. https://doi.org/10.1056/NEJMra1804281
    1. Infusino, I., Braga, F., Dolci, A., & Panteghini, M. (2012). Soluble transferrin receptor (sTfR) and sTfR/log ferritin index for the diagnosis of iron‐deficiency anemia a meta‐analysis. American Journal of Clinical Pathology, 138, 642–649. https://doi.org/10.1309/AJCP16NTXZLZFAIB
    1. Masini, G., Graham, F. J., Pellicori, P., Cleland, J. G. F., Cuthbert, J. J., Kazmi, S., Inciardi, R. M., & Clark, A. L. (2022). Criteria for iron deficiency in patients with heart failure. Journal of the American College of Cardiology, 79, 341–351. https://doi.org/10.1016/j.jacc.2021.11.039
    1. Mazer, C. D., Hare, G. M. T., Connelly, P. W., Gilbert, R. E., Shehata, N., Quan, A., Teoh, H., Leiter, L. A., Zinman, B., Jüni, P., Zuo, F., Mistry, N., Thorpe, K. E., Goldenberg, R. M., Yan, A. T., Connelly, K. A., & Verma, S. (2020). Effect of Empagliflozin on erythropoietin levels, iron stores, and red blood cell morphology in patients with type 2 diabetes mellitus and coronary artery disease. Circulation, 141, 704–707. https://doi.org/10.1161/CIRCULATIONAHA.119.044235

LinkOut - more resources